Comparison of effects between higher dosages of infliximab and switching to other biologics for rheumatoid arthritis patients with less responsiveness to infliximab therapy (cHAMLET)
Phase 4
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-UMIN000002340
- Lead Sponsor
- Department of Rheumatosurgery, Osaka City University Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
Patients whose DAS28-ESR are below 3.2 (DAS28-CRP>2.7) after low-dose infliximab (3mg/Kg) therapy at least 5 times
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method DAS28, EULAR responsiveness
- Secondary Outcome Measures
Name Time Method mHAQ, The number and dosages of concomitant medication